All In Biotech

NDA 215985 · Arcutis

Zoryve

Roflumilast · Topical · Phosphodiesterase 4 Inhibitor

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jul 29, 2022

Approved uses

5

Original approval plus efficacy supplements

Registered trials

129

45 Phase 3, 14 recruiting

FAERS reports

3,191

1,832 serious, 198 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

ZORYVE cream is a phosphodiesterase 4 inhibitor: Plaque Psoriasis ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older. ( 1.1 ) Atopic Dermatitis ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ( 1.2 ) ZORYVE cream, 0.05%, is indicated for the topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ( 1.2 ) 1.1 Plaque Psoriasis ZORYVE ® cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older. 1.2 Atopic Dermatitis ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

Mechanism: Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of PDE4. Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic 3′,5′-adenosine monophosphate [cyclic AMP] metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP. The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZORYVE · ROFLUMILAST 0.05% · CREAM, TOPICAL · Prescription
  • ZORYVE · ROFLUMILAST 0.3% · CREAM, TOPICAL · Prescription
  • ZORYVE · ROFLUMILAST 0.15% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Roflumilast" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea467
  • drug ineffective293
  • off label use272
  • chronic obstructive pulmonary disease251
  • diarrhoea239
  • pneumonia229
  • asthma215
  • cough205
  • nausea191
  • headache179
  • wheezing169
  • pruritus161

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
2012178
2013221
2014203
201576
201628
201732
201873
201981
202088
2021100
2022116
2023235
2024398
2025650
2026709

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zoryve (Roflumilast)

2024 spending

$25.6M

Beneficiaries

15,047

29,028 claims

Per beneficiary

$1,704

$14.15 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$6,972,386
2024$25,639,364

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: Arcutis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.